These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3054673)

  • 1. A hypothesis concerning the relationship of cellular pharmakokinetics to optimal scheduling of anti-cancer agents.
    Weiss AJ; Manthei R
    Oncology; 1988; 45(6):448-52. PubMed ID: 3054673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian cancer therapy.
    Hrushesky WJ; Bjarnason GA
    J Clin Oncol; 1993 Jul; 11(7):1403-17. PubMed ID: 8315438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.
    Masson E; Zamboni WC
    Clin Pharmacokinet; 1997 Apr; 32(4):324-43. PubMed ID: 9113440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian cancer pharmacodynamics.
    Hrushesky WJ
    Ann Ist Super Sanita; 1993; 29(4):705-10. PubMed ID: 7985931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronotherapy of growth factors.
    Wood PA
    J Infus Chemother; 1995; 5(1):20-3. PubMed ID: 7634172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The significance of chronopharmacology for oncology].
    Hallek M; Lévi F; Haen E; Emmerich B
    Onkologie; 1989 Oct; 12(5):230-8. PubMed ID: 2685689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacologic approach to dosage intensification.
    Weiss AJ
    Sel Cancer Ther; 1990; 6(3):129-34. PubMed ID: 2281202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical cancer chronotherapy trials: a review.
    Bjarnason GA
    J Infus Chemother; 1995; 5(1):31-7. PubMed ID: 7634175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the chronotherapeutic index in the experimental animal laboratory.
    Halberg E; Cornélissen G; Halberg F
    In Vivo; 1992; 6(4):371-85. PubMed ID: 1520840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronochemotherapy for cancer].
    Akazawa S
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1191-202. PubMed ID: 9279336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel chronopharmacology in mice.
    Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
    Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of DNA synthesis as an indication of drug toxicity and as a guide for scheduling cancer therapy.
    Wheeler GP; Alexander JA
    Cancer Treat Rep; 1978 May; 62(5):755-69. PubMed ID: 657161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian optimization of treatment time using DNA replication-dependent cell-cycle-specific halogenated pyrimidines.
    Klevecz RR; Brown LP; Morgan RJ; Carroll M
    J Infus Chemother; 1995; 5(1):15-9. PubMed ID: 7634171
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate.
    Natoli C; Salini V; Irtelli L; Martino MT; Garufi C; Grassadonia A; Fiorentino B; Iacobelli S
    Anticancer Res; 1996; 16(3A):1275-9. PubMed ID: 8702250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.